STOCK TITAN

Myriad Genetics CFO receives 121,379 stock options

The award is subject to continued service through November 6, 2029, and expires on November 6, 2036.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Myriad Genetics (MYGN) Chief Financial Officer Benjamin Richard Wheeler received a one-time non-qualified stock option grant on November 6, 2026, as a retention award. The option covers 121,379 shares of common stock and has a $5.92 exercise price, equal to the common stock’s closing price on the grant date. It vests and becomes exercisable in full on November 6, 2029, subject to his continued service through that date, and expires on November 6, 2036.

Insider Wheeler Benjamin Richard
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Time-Based Stock Option F1, F2 121,379 $0.00 $0.00
Holdings After Transaction: Time-Based Stock Option — 121,379 options (Direct)
Footnotes (2)
  1. F1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.
  2. F2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.
Option shares after grant 121,379 options covering common shares Reported position following the grant
Exercise price $5.92 per share Equal to the common stock’s closing price on November 6, 2026
Vesting and exercisability date November 6, 2029 Vests and becomes exercisable in full, subject to continued service
Expiration date November 6, 2036 Expiration of the option
non-qualified stock option financial
"one-time non-qualified stock option granted"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
retention award financial
"granted as a retention award"
exercise price financial
"The exercise price equals the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests and becomes exercisable in full financial
"vests and becomes exercisable in full on November 6, 2029"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MYGN stock options did CFO Benjamin Richard Wheeler receive?

Benjamin Richard Wheeler received an option covering 121,379 shares of common stock, with a $5.92 exercise price.

When do Benjamin Richard Wheeler’s MYGN options vest and expire?

The option vests and becomes exercisable in full on November 6, 2029, subject to his continued service through that date, and expires on November 6, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wheeler Benjamin Richard

(Last)(First)(Middle)
322 NORTH 2200 WEST

(Street)
SALT LAKE CITY UTAH 84116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Time-Based Stock Option(1)$5.92(2)11/06/2026A121,37911/06/202911/06/2036Common Stock121,379$0121,379D
Explanation of Responses:
1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.
2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.
Remarks:
By: Justin Hunter For: Benjamin R. Wheeler11/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading